Skip to content

Serotonin research published in 2013

32 studies whose primary subject is serotonin were published in 2013, up from 25 in 2012. Newest first. Back to the serotonin overview

Studies

Subanesthetic doses of ketamine transiently decrease serotonin transporter activity: a PET study in conscious monkeys.

Neuropsychopharmacology December 2013 Shigeyuki Yamamoto, Hiroyuki Ohba, Shingo Nishiyama et al.

Subanesthetic doses of ketamine, an N-methyl-D-aspartic acid (NMDA) antagonist, have a rapid antidepressant effect which lasts for up to 2 weeks. However, the neurobiological mechanism regarding this effect remains unclear. In the present study, the effects of subanesthetic doses of ketamine on serotonergic systems in conscious monkey brain were investigated. Five young monkeys underwent four...

D-serine deficiency attenuates the behavioral and cellular effects induced by the hallucinogenic 5-HT2A receptor agonist DOI

Behavioural Brain Research November 20, 2013 Martin A. Santini, D. Balu, M. Puhl et al.

Both the serotonin and glutamate systems have been implicated in the pathophysiology of schizophrenia, as well as in the mechanism of action of antipsychotic drugs. Psychedelic drugs act through the serotonin 2A receptor (5-HT2AR), and elicit a head-twitch response (HTR) in mice, which directly correlates to 5-HT2AR activation and is absent in 5-HT2AR knockout mice. The precise mechanism of...

Sex‐dependent long‐term effects of adolescent exposure to THC and/or MDMA on neuroinflammation and serotoninergic and cannabinoid systems in rats

British Journal of Pharmacology November 15, 2013 Ana Belén López-rodríguez, Alvaro Llorente‐berzal, Luis Miguel García‐segura et al. 50 citations

Background and Purpose Many young people consume ecstasy as a recreational drug and often in combination with cannabis. In this study, we aimed to mimic human consumption patterns and investigated, in male and female animals, the long‐term effects of Δ 9 ‐tetrahydrocannabinol ( THC ) and 3,4‐methylenedioxymethamphetamine ( MDMA ) on diverse neuroinflammation and neurotoxic markers. Experimental...

3,4-methylenedioxymethamphetamine (MDMA): current perspectives

Substance Abuse and Rehabilitation November 1, 2013 Jerry Meyer 93 citations

Ecstasy is a widely used recreational drug that usually consists primarily of 3,4-methylenedioxymethamphetamine (MDMA). Most ecstasy users consume other substances as well, which complicates the interpretation of research in this field. The positively rated effects of MDMA consumption include euphoria, arousal, enhanced mood, increased sociability, and heightened perceptions; some common...

Independent of 5-HT1A receptors, neurons in the paraventricular hypothalamus mediate ACTH responses from MDMA.

Neuroscience Letters October 25, 2013 Dmitry V Zaretsky, Maria V Zaretskaia, Joseph A Dimicco et al.

Acute and chronic complications from the substituted amphetamine 3,4-methylenedioxymethamphetamine (MDMA) are linked to activation of the hypothalamic-pituitary-adrenal (HPA) axis. How MDMA activates the HPA axis is not known. HPA responses to stress are known to be mediated through the paraventricular (PVH) hypothalamus and to involve serotonin-1a (5-HT1A) receptors. We sought to determine if...

Nonlinear Pharmacokinetics of (±)3,4-Methylenedioxymethamphetamine (MDMA) and Its Pharmacodynamic Consequences in the Rat

Drug Metabolism and Disposition October 19, 2013 Marta Concheiro, Michael H. Baumann, Karl B. Scheidweiler et al. 32 citations

3,4-Methylenedioxymethamphetamine (MDMA) is a widely abused illicit drug that can cause severe and even fatal adverse effects. However, interest remains for its possible clinical applications in posttraumatic stress disorder and anxiety treatment. Preclinical studies to determine MDMA's safety are needed. We evaluated MDMA's pharmacokinetics and metabolism in male rats receiving 2.5, 5, and 10...

5-HT2 receptors-mediated modulation of voltage-gated K+ channels and neurophysiopathological correlates.

Experimental Brain Research October 2013 Maria Cristina D'Adamo, Ilenio Servettini, Luca Guglielmi et al.

The activity of voltage-gated K(+) channels (Kv) can be dynamically modulated by several events, including neurotransmitter stimulated biochemical cascades mediated by G protein-coupled receptors such as 5-HT2 receptors (5-HT2Rs). Activation of 5-HT2A/CR inhibits the Shaker-like K(+) channels Kv1.1 and Kv1.2, and this modulation involves the dual coordination of both RPTPα and distinct tyrosine...

5‐(2‐Aminopropyl)indole (5‐IT): a psychoactive substance used for recreational purposes is an inhibitor of human monoamine oxidase (MAO)

Drug Testing and Analysis September 20, 2013 Tomás Herraiz, Simon D. Brandt 25 citations

5-(2-Aminopropyl)indole (5-IT) is a psychoactive compound that has recently been associated with several fatal and non-fatal intoxications in a number of European countries. There are indications that acute effects may include symptoms of monoaminergic (e.g. serotonin) toxicity and one mechanism involved in the increase of serotonin levels includes the inhibition of monoamine oxidase. This...

Serotonergic hallucinogens as translational models relevant to schizophrenia

The International Journal of Neuropsychopharmacology August 13, 2013 Adam L. Halberstadt, Mark A. Geyer 66 citations

Abstract One of the oldest models of schizophrenia is based on the effects of serotonergic hallucinogens such as mescaline, psilocybin, and (+)-lysergic acid diethylamide (LSD), which act through the serotonin 5-HT2A receptor. These compounds produce a ‘model psychosis’ in normal individuals that resembles at least some of the positive symptoms of schizophrenia. Based on these similarities, and...

Effects of combined treatment with mephedrone and methamphetamine or 3,4-methylenedioxymethamphetamine on serotonin nerve endings of the hippocampus

Life Science July 24, 2013 M. Angoa-Perez, Michael J. Kane, Nieves Herrera-Mundo et al. 41 citations

Aims Mephedrone is a stimulant drug of abuse with close structural and mechanistic similarities to methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA). Although mephedrone does not damage dopamine nerve endings it increases the neurotoxicity of amphetamine, methamphetamine and MDMA. The effects of mephedrone on serotonin (5HT) nerve endings are not fully understood, with some...

Spatiotemporal Brain Dynamics of Emotional Face Processing Modulations Induced by the Serotonin 1A/2A Receptor Agonist Psilocybin

Cerebral Cortex July 16, 2013 Fosco Bernasconi, André Schmidt, Thomas Pokorny et al. 62 citations

Emotional face processing is critically modulated by the serotonergic system. For instance, emotional face processing is impaired by acute psilocybin administration, a serotonin (5-HT) 1A and 2A receptor agonist. However, the spatiotemporal brain mechanisms underlying these modulations are poorly understood. Here, we investigated the spatiotemporal brain dynamics underlying psilocybin-induced...

Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model.

Neuropharmacology July 2013 Clinton E. Canal, Raymond G Booth, Drake Morgan

There are seemingly conflicting data in the literature regarding the role of serotonin (5-HT) 5-HT2C receptors in the mouse head-twitch response (HTR) elicited by the hallucinogenic 5-HT2A/2B/2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine (DOI). Namely, both 5-HT2C receptor agonists and antagonists, regarding 5-HT2C receptor-mediated Gq-phospholipase C (PLC) signaling, reportedly attenuate...

Role of the 5-HT₂A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice.

Neuropharmacology July 2013 Adam L. Halberstadt, Susan B Powell, Mark A. Geyer

The 5-HT₂A receptor mediates the effects of serotonergic hallucinogens and may play a role in the pathophysiology of certain psychiatric disorders, including schizophrenia. Given these findings, there is a need for animal models to assess the behavioral effects of 5-HT₂A receptor activation. Our previous studies demonstrated that the phenylalkylamine hallucinogen and 5-HT₂A/₂C agonist...

Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations

Journal of Neuroscience June 19, 2013 Michael Kometer, André Schmidt, Lutz Jäncke et al. 357 citations

Visual illusions and hallucinations are hallmarks of serotonergic hallucinogen-induced altered states of consciousness. Although the serotonergic hallucinogen psilocybin activates multiple serotonin (5-HT) receptors, recent evidence suggests that activation of 5-HT2A receptors may lead to the formation of visual hallucinations by increasing cortical excitability and altering visual-evoked...

Age differences in (±) 3,4‐methylenedioxymethamphetamine (MDMA)‐induced conditioned taste aversions and monoaminergic levels

Developmental Psychobiology June 15, 2013 Jennifer L. Cobuzzi, Kayla Siletti, Zachary E. Hurwitz et al. 15 citations

Preclinical work indicates that adolescent rats appear more sensitive to the rewarding effects and less sensitive to the aversive effects of abused drugs. The present investigation utilized the conditioned taste aversion (CTA) design to measure the relative aversive effects of (±)3,4-methylenedioxymethamphetamine (MDMA; 0, 1.0, 1.8, or 3.2 mg/kg) in adolescent and adult Sprague-Dawley rats....

Acquisition of MDMA self‐administration: pharmacokinetic factors and MDMA‐induced serotonin release

Addiction Biology June 14, 2013 Sarah Bradbury, Judith Bird, Joyce Colussi‐mas et al. 59 citations

Abstract The current study aimed to elucidate the role of pharmacokinetic ( PK ) parameters and neurotransmitter efflux in explaining variability in (±) 3, 4‐methylenedioxymethamphetamine ( MDMA ) self‐administration in rats. PK profiles of MDMA and its major metabolites were determined after the administration of 1.0 mg/kg MDMA (iv) prior to, and following, the acquisition of MDMA...

Preclinical models of antipsychotic drug action

The International Journal of Neuropsychopharmacology June 10, 2013 José L. Moreno, Javier González-Maeso 30 citations

Abstract One of the main obstacles faced by translational neuroscience is the development of animal models of psychiatric disorders. Behavioural pharmacology studies indicate that psychedelic drugs, such as lysergic acid diethylamide (LSD) and dissociative drugs, such as phencyclidine (PCP), induce in healthy human volunteers psychotic and cognitive symptoms that resemble some of those observed...

Recurrent seizures and serotonin syndrome following "2C-I" ingestion.

Journal of Medical Toxicology June 1, 2013 Adam Bosak, Frank Lovecchio, Michael Levine 59 citations

The phenethylamines, including 2, 5 dimethoxy-4-iodophenethylamine, commonly referred to as 2C-I, have recently emerged as a new class of designer drugs. Cases of toxicity from these drugs are not well described in the literature. This case report describes a 19 year-old male who insufflated 2C-I. Following the ingestion, the patient developed recurrent seizures, and was taken to the emergency...

DOI: 10.1007/s13181-013-0287-x (opens in new tab) Full text (opens in new tab) 2c-i toxicity 2c-i poisoning 2c-i adverse effects 2c-i overdose +14

Single oral doses of (±) 3,4-methylenedioxymethamphetamine (‘Ecstasy’) produce lasting serotonergic deficits in non-human primates: relationship to plasma drug and metabolite concentrations

The International Journal of Neuropsychopharmacology May 1, 2013 Melanie Mueller, Jie Yuan, Una D. Mccann et al.

Abstract: Repeated doses of the popular recreational drug methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) are known to produce neurotoxic effects on brain serotonin (5-HT) neurons but it is widely believed that typical single oral doses of MDMA are free of neurotoxic risk. Experimental and therapeutic trials with MDMA in humans are underway. The mechanisms by which MDMA produces neurotoxic...

Enhanced prefrontal serotonin 2A receptor signaling in the subchronic phencyclidine mouse model of schizophrenia.

Journal of Neuroscience Research May 1, 2013 Martin A. Santini, Cecilia Ratner, Susana Aznar et al.

Prefrontal serotonin 2A receptors (5-HT2A Rs) have been linked to the pathogenesis and treatment of schizophrenia. Many antipsychotics fully occupy 5-HT2A R at clinical relevant doses, and activation of 5-HT2A receptors by lysergic acid diethylamide (LSD) and LSD-like drugs induces a schizophrenia-like psychosis in humans. Subchronic phencyclidine (PCP) administration is a well-established...